Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.47 |
| ▸ | RAB9A | P51151 | 6/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8513475 | 0.83 | NPC1 (0.42) | NPC1RAB9AL3MBTL1MAPTMEN1 | |
| SCHEMBL16210072 | 0.83 | MEN1 (0.59) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL12441003 | 0.79 | MEN1 (0.56) | NPC1RAB9AL3MBTL1MAPTMEN1 | |
| SCHEMBL8501004 | 0.77 | NPC1 (0.70) | NPC1RAB9AL3MBTL1RXFP1MAPT | |
| SCHEMBL16320822 | 0.76 | CYP2A6 (0.62) | NPC1RAB9AMAPTKMT2ALMNA | |
| Ammonia Solution, Strong SCHEMBL27968646 | 0.76 | NPC1 (0.68) | NPC1RAB9AL3MBTL1RXFP1MAPT | |
| SCHEMBL12514786 | 0.75 | TP53 (0.47) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL8891737 | 0.75 | KDM4E (0.41) | NPC1RAB9AL3MBTL1MAPTMEN1 | |
| SCHEMBL2650448 | 0.74 | L3MBTL1 (0.49) | NPC1RAB9AL3MBTL1RXFP1MAPT | |
| SCHEMBL2678667 | 0.74 | NPC1 (0.51) | NPC1RAB9AL3MBTL1RXFP1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173807-B2 | Pyridine, pyrimidine and pyrazine derivatives as GPCR agonists | PROSIDION LIMITED (GB) | 2012-05-08 | — | — | US | disclosed |
| US-8173807-B2 | Pyridine, pyrimidine and pyrazine derivatives as GPCR agonists | PROSIDION LIMITED (GB) | 2012-05-08 | — | — | US | disclosed |
| US-8173807-B2 | Pyridine, pyrimidine and pyrazine derivatives as GPCR agonists | PROSIDION LIMITED (GB) | 2012-05-08 | — | — | US | disclosed |
| EP-1838698-B1 | PYRIMIDINE DERIVATIVES AS GPCR AGONISTS | PROSIDION LTD (GB) | 2010-09-01 | — | — | EP | disclosed |
| US-20100035897-A1 | Pyridine, pyrimidine and pyrazine derivatives as gpcr agonists | PROSIDION LIMITED (GB) | 2010-02-11 | — | — | US | disclosed |
| US-20100035897-A1 | Pyridine, pyrimidine and pyrazine derivatives as gpcr agonists | PROSIDION LIMITED (GB) | 2010-02-11 | — | — | US | disclosed |
| US-20100035897-A1 | Pyridine, pyrimidine and pyrazine derivatives as gpcr agonists | PROSIDION LIMITED (GB) | 2010-02-11 | — | — | US | disclosed |
| EP-1838698-A1 | PYRIMIDINE DERIVATIVES AS GPCR AGONISTS | Prosidion Limited (GB) | 2007-10-03 | — | — | EP | disclosed |
| WO-2006070208-A1 | PYRIDINE, PYRIMIDINE AND PYRAZINE DERIVATIVES AS GPCR AGONISTS | PROSIDION LTD. (GB) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035897-A1 | Pyridine, pyrimidine and pyrazine derivatives as gpcr agonists | GPR119, GPR52, GPR65 | NPC1 2333/4885RAB9A 1249/4885L3MBTL1 4020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.